Welcome to Drug Discovery 2019

Home , Alderley Park, BioCity Nottingham, MedImmune, UCL School of Pharmacy

www.elrig.org Welcome to Drug Discovery 2019

As Scientific Program chairs it is our great pleasure to welcome you back to Liverpool for the 13th Annual ELRIG Drug Discovery event. Our organising committee and session chairs have been working hard since late 2018 and thanks to them we have again been able to assemble a world-class line up of scientific speakers. This year we have 8 thematic tracks over 2 days with over 50 invited speakers, over 100 posters and as always a sold out and vibrant exhibition hall. We encourage you to get to as much of the science as you possibly can and to take full advantage of the exhibitor’s expertise and knowledge to improve your own discovery sciences. The vendor presence at ELRIG ensures that these conferences are of minimal cost to attendees, so please show your appreciation by visiting the booths and asking as many probing and difficult questions of their technology as possible. With these questions they are better equipped to supply us with the tools of the future to make the next set of discoveries. We are sure there will be something for everyone at this year’s Drug Discovery. We have tried to reflect hot topics and trends in the Drug Discovery field in this year’s tracks and we invite our speakers to take a look back at the future. We aim to ponder on both how we have arrived at this exciting era of drug discovery and to look ahead to what the future may hold. We are also delighted to welcome sessions hosted by the British Pharmacological Society and Cancer Research UK, focusing on ion channels and oncology drug discovery respectively. We would again like to thank Rhona Bennett, Clare Cockerham, Sanj Kumar and Tara Shanks in the ELRIG office for their fantastic contribution in shepherding ourselves and the Program Chairs through the organising process. Without their help, together with the all the other volunteers, this meeting would not be possible. Finally, without you, the meeting delegate, we have nothing too. We thank you in advance for your participation and look forward to connecting with you over the next couple of days. As always, we welcome your feedback on how we can further improve the agenda to ensure the growth and success of ELRIG Drug Discovery for the future. Have fun in Liverpool and enjoy the opportunity to discuss emerging Science within a vibrant and collegiate environment!

Chun-wa Chung Tim Hammonds Katy Kettleborough (GlaxoSmithKline) (Cancer Research UK) (LifeArc)

A Message from the Chair of ELRIG, Steve Rees

On behalf of ELRIG I would like to welcome you to the 13th Drug Discovery meeting and our return to Liverpool. During 2019 ELRIG has held four outstanding scientific events attracting over 1300 delegates. With the 1400 scientists expected to attend Drug Discovery this will be a record year for ELRIG in terms of meeting delegates and vendor exhibitions. Alongside this our networking events programme is now established in major science centres across the UK, and the Early Career Professional Work group has run a series of events to engage with, and support, junior scientists as they embark on their careers.

We have an exciting scientific program in place for 2020. Following the success of our first meeting on CRISPR in Drug Discovery we will be revisiting this topic in March in Cambridge. For the first time our Research and Innovation meeting will be held in Oxford in April, we will be returning to Gothenburg for a Cell Therapy meeting in June and Stevenage for our Flow Cytometry and Imaging meeting in the autumn. Alongside this we look forward to returning to the ExCeL in London for Drug Discovery 2020 in October.

The success of ELRIG is dependent upon the many volunteers who give their time freely to create our meetings and other events. Volunteers are supported by an outstanding ELRIG office team; Sanj Kumar, Tara Shanks, Rhona Bennett and Clare Cockerham. I would like to thank everyone involved in ELRIG for the work that they do for this organisation.

Looking ahead to the next two days we have an outstanding scientific program to look forward too, together with our largest ever vendor exhibition. I would like to thank the science committee, session chairs, speakers, exhibitors and of course you for attending this meeting. As I have said before my challenge to all delegates is to learn something new, meet someone new and see something new to advance your research. Have a great few days!

#ELRIG Drug Discovery 2019 Session Chairs

Tuesday 5th November 2019 Wednesday 6th November 2019

Cellular Models of Disease Molecular and Cellular Imaging

Paul Andrews Robert Vries Michael Hennig (University of Dundee) (Hubrecht Organoid (leadXpro) Technology)

Chemical biology – re-defining target Biomarkers Strategies tractability and therapeutic class in Drug Discovery

Marcus Bantscheff Satpal Virdee Sally Price Ian Pike (Cellzome) (University of Dundee) (Medicines Discovery (Ian Pike Consulting) Catapult)

Big Data and Artificial Intelligence Hit Finding Strategies

Ola Engkvist Hugo Ceulemans Philip Gribbon Rosemary Burke (AstraZeneca) (Jansen pharmaceuticals) (Fraunhofer IME (Institute of Cancer Screening Port) Research)

Targeting Ion Channels for Drug Discovery Oncology Drug Discovery hosted by the British Pharmacological Society hosted by Cancer Research UK

Sarah Nickolls David Kendall Graeme Walker Heather McKinnon (GlaxoSmithKline) (Pharmnovo) (Cancer Research UK (The Beatson Institute Manchester Institute) for Cancer Research)

#ELRIG Plenary Keynote Speakers

Dr. Mene Pangalos (AstraZeneca)

“Turning science into medicine: Hot trends and the business landscape” Tuesday 5th November 2019: 09:15: Room 3A

The future treatment for many of today’s diseases lies in discovering new biology, understanding and challenging scientific hypotheses, to develop novel therapies. Improving R&D productivity is critical to the success ofdrug discovery, with failure rates from pre-clinical development to launch often in excess of 90 percent. The advent of data science and artificial intelligence, coupled with ever more sophisticated platform technologies, suchas dynamic multi-omics brings with it an expanding list of pathways and targets to pursue - and with-it new drug discovery challenges. Exploring novel drug modalities which complement existing strengths in small molecule and biologic platforms has the potential to open new therapeutic options, and to help us prosecute drug targets traditionally viewed as intractable. Over the past few years we have made significant progress across seven additional drug discovery platforms, complementing existing capabilities in chemistry and protein engineering. These include modified mRNA therapies, antisense oligonucleotides (ASOs), oligonucleotide conjugates, bicyclic peptides, proteolysis targeting chimeras (PROTACs), anticalins and CRISPR. By combining new technologies, focusing on medical understanding, challenging scientific hypotheses and driving strategic private and academic partnerships, we are making real progress in our ability to define and prosecute novel treatment approaches for a variety of difficult to treat diseases.

Dr. Fiona Marshall (MSD) “Tackling diseases of ageing – the application of new approaches in drug discovery and development.” Wednesday 6th November 2019: 09:10: Room 3A

Populations around the world are increasing in age and this is leading to a rise in the incidence of diseases associated with ageing. In particular, the number of people with neurodegenerative disease is placing a burden on families and healthcare systems. Despite many recent failures in developing treatments for dementia there is much hope for the future. New insights from genetics is increasing our understanding of key mechanisms underlying ageing and related diseases. Multiple therapeutic modalities are being evaluated to modulate genes and proteins involved in disease in human cell models. Finally, novel biomarkers and imaging techniques can be utilized to diagnose and stratify patients and to track the progression of disease. In combination these advances are set to alter future treatments for diseases of ageing.

Industry Insider Presentation Dr. Melanie Lee (LifeArc)

“Nurturing effective translation” Wednesday 6th November 2019: 10:20: Room 3A

LifeArc has a 25-year legacy of collaborating with scientists, academics and industry on diagnostics and therapies, enhancing and protecting innovation, and advancing promising research. We have been enormously successful in these endeavours. But the world we deliver products into doesn’t stand still. Healthcare, science and technology are ever-changing, and this applies to translation as well. In the future, pharmaceutical companies will still need well prepared, validated therapeutic opportunities. But to be differentiated, the products will need to carry more information than they have in the past. Diagnostics will be able to identify much earlier those patients at likelihood of developing a condition. Advances in data analytics and genomic information will enable greater targeting of medicines to a sub-set of patients. How do we nurture effective translation as the world of digital informatics rapidly evolves?

#ELRIG Information for Participants

Registration Awards at Drug Discovery 2019

Registration will take place on the ground floor. Please ELRIG Early Career Professional Impact Award collect your name badge and event programme from the registration desk. For security reasons it is essential sponsored by to wear your badge at all times whilst attending Drug Discovery 2019.

Attendees will not be allowed access to any lecture Award Presentation: Tuesday 5th November theatre or the exhibition area without a name badge. The 08:50 - 09:05 registration desk will open during the following times: Room 3A

Tuesday 5th November: 08:00–16:30 Winner Talk: Wednesday 6th November Wednesday 6th November: 08:00–14:00 12:20 - 12:40 Room 3A ELRIG Mobile App SelectScience Seal of Quality Awards Download the free ELRIG app and access all our Award Presentation: Tuesday 5th November conference information, programme and more from your 17:15 - 17:45 phone or tablet. Training zone in exhibition hall • View the event programme • View presentation and poster abstracts Cancer Research UK Oncology Poster Award • View speaker profiles Award Presentation: Wednesday 6th November • View the exhibitor guide 16:00 - 16:15 • View the delegate and exhibitor list Room 3A • Organise your day with your own favourites list • Share your profile as vCard and QR Code and scan exhibitor QR code information tags. • Network – contact delegates, other exhibitors and speakers easily through opt-in directories and ELRIG Innovation Award integration with Linked-In, Twitter and Facebook Award Presentation: Wednesday 6th November 16:15 - 16:30 You can download the ELRIG app by visiting the app Room 3A store appropriate to your tablet or smart phone, scanning the QR code below or visiting the ELRIG website: Drug Discovery 2019 Technology Prize Award Presentation: Wednesday 6th November www.elrig.org/mobile-app/ 16:15 - 16:30 Room 3A

Drug Discovery 2019 Poster Prize Award Presentation: Wednesday 6th November 16:15 - 16:30 Room 3A

Connecting to Free WI-FI at ACC, Liverpool

1. Enable the wireless function on your device 2. Connect to the Free_Wifi SSID (wireless network) 3. Browse to a web site of your choice e.g. www.accliverpool.com 4. You will be re-directed to the ACC Liverpool Landing Page 5. Click on the ‘FREE WI-FI ACCESS’ button 6. The page of your choice will then load.

#ELRIG ACC, Liverpool Floor plan

Exhibitor Booth Locations

acCELLerate GmbH D10 CRB Discovery H1 NanoTemper Technologies B12 Admescope A5 Creoptix AG H2 National Physical Laboratory B1 Analytik Jena AG H6 Cancer Research UK G4 Nexcelom Bioscience Ltd B7 Andrew Alliance G5 CytoSmart Technologies B.V. H4 PAA F3 Applied Scientific Technologies UK Dispendix A3 Pelago Bioscience AB E3 Ltd B8 Eurofins Discovery G6 Promega UK Ltd F1 Aptamer Group Limited H8 Fluidic Analytics F4 Proteome Sciences Plc G3 Ardigen - on hold B4 Fluidigm UK Limited F6 Reaction Biology Corporation D2 Astech Projects Ltd E6 Formulatrix, Inc. C5 Repositive B13 Aurelia Biosciences F9 GC biotech G11 REPROCELL D9 Beckman Coulter Life Sciences & Genedata AG G1 RxNet G2 Labcyte Inc J1 Greiner Bio One D3 Sarstedt Ltd D6 BioAsent H5 Hamamatsu Photonics UK Ltd B14 Sartorius Stedim Biotech C6 Bioivt B5 Hamilton Bonaduz AG B9 Sphere Fluidics Limited D8 Bio-Rad Laboratories Ltd G15 HighRes Biosolutions Ltd F5 STEMCELL Technologies B10 BioStrata A2 I&L Biosystems UK LTD H7 Stratech Scientific Ltd C2 BioTek Instruments Ltd C1 INTEGRA Bioscience Ltd E8 Sygnature Discovery B11 BlueCatBio GmbH D5 Labcyte Inc & Beckman Coulter Life Synthago H3 BMG LABTECH Ltd G13 Sciences J1 Taconic E11 British Pharmacological Society B2 LabLogic Systems Limited D1 Tecan UK Ltd E1 Brooks Lifesciences G10 LGC - ATCC E10 Thermo Fisher Scientific C3 Cambridge Bioscience E4 LifeArc G12 Tissue Solutions D4 CAS A1 LightOx B16 Titian Software Ltd D7 CBRE Integrated Laboratory Medicines Discovery Catapult F2 Twist Bioscience B15 Solutions F8 Merck A6 UPM-Kymmene Corporation E7 Cell Signaling F7 Metrion Biosciences Ltd G16 XenoGesis Ltd G8 ChemoMetec C9 Miltenyi Biotec Ltd B3 Zinsser Analytic GmbH A7 Cisbio G7 Mimetas B.V. A4

#ELRIG ACC Exhibition Hall 2 Floor plan

Innovation Zone Booth Locations Media Zone Booth Locations

Atelerix Ltd IZ8 CamBioScience MZ1 BioMedha Limited IZ10 Drug Discovery News MZ5 British Society for Nanomedicine IZ12 Drug Discovery World MZ6 Cell & Soft IZ3 Drug Target Review MZ4 Cell Guidance Systems IZ1 SelectScience MZ7 Cellbox Solutions IZ2 Technology Networks MZ3 Cytomos Limited IZ6 UK Pharmacogenetics & Stratified Enzymlogic IZ7 Medicine Network MZ8 Imrali Inventions IZ11 Zyme Communications MZ2 innoVitro GmbH IZ9 Manchester BIOGEL IZ13 Career Zone Booth Locations Microlight3D IZ4 ScreenIn3D IZ14 GlaxoSmithKline CZ1 Stream Bio Ltd IZ5 Langton Howarth CZ2

#ELRIG What’s On at Drug Discovery 2019

Drug Discovery 2019 is free-to-attend: Learning Paths: ELRIG are proud to offer free to attend scientific meetings Follow our suggested agendas through the meeting to & networking events across the UK & Europe learn as much as possible about some of the hottest topics in Drug Discovery! World class speakers: Our speakers are leading experts in their fields who will Early Career Professional Development: be discussing cutting edge research over the 2 days. For those starting their careers in drug discovery, networking sessions, panel discussion and Workshop. Innovation Zone: ELRIG supports fledgling biotech companies, who will Networking Events: be exhibiting their latest technologies in the Innovation Meet up with 1200 fellow Drug Discovery practitioners at Zone our network event Training & Workshops: Vendor Exhibition: Free to attend training courses on the latest scientific Visit our vendor exhibition in the main exhibition hall to techniques and workshops on practical aspects of discuss the latest products on the market ground breaking technologies and techniques

#ELRIG Early Career Professionals

Careers in Drug Discovery: Where to next? Careers in Drug Discovery: Your CV for Industry Tuesday 5th November Wednesday 6th November 14:00 - 15:00 11:00 - 12:30 Room 11B Room 11B

Are you a post-doc, postgraduate, early career researcher Are you a post-doc, postgraduate, early career or professional (ECP) scientist looking to start or build researcher or professional (ECP) scientist looking to start your career in drug discovery? If so, understanding the or build your career in drug discovery? If so, writing a wide array of opportunities and career paths for you compelling, industry relevant curriculum vitae is critical beyond academia, and how to make that step, is critical to maximize your chance of success. to your success. Join us at our ECP CV workshop event: Join us at our ECP panel discussion event: • Learn from industry hiring managers, employer • Hear panellists discuss and share their experiences internal recruiters and recruitment consultants as to and personal stories in making this transition the key requirements of your CV • Increase awareness of different roles and career • Get practical advice and feedback on your CV and paths in the drug discovery industrial community optimize to be ‘industry appropriate’ • Learn more about career and professional • Meet other ECP scientists & expand your network development support available to you • Prepare for the next exciting step in your career! • Meet other ECP scientists & expand your network • Prepare for the next exciting step in your career!

Chair: Drug Discovery 2019 Training Zone Andrew Whale (Immunocore) Throughout the two days, CamBioScience will be Panellists: running a series of virtual lectures and training sessions Lois Manton-O’Byrne (SelectScience) in the training zone using silent disco and virtual reality Sarah Major (Charnwood Molecular) technology. No pre-booking is necessary. Just select a Siobhan Leonard (LifeArc) time (you will find these listed after the workshops) and Matthew Tomlinson (Sartorius) turn up!

Careers in Drug Discovery: Network like a boss Drug Discovery 2019 Learning Paths: Your Tuesday 5th November Learning Experience Starts Here Career & Innovation Zone 17:30 - 18:30 As an Early Career Professional, with 50 free-to-attend talks, workshops and technical training sessions, Drug Are you a post-doc, postgraduate, early career Discovery 2019 is THE place to learn about some of researcher or professional (ECP) scientist looking to start the hottest topics in life science research. Follow our or build your career in drug discovery? If so, building suggested learning paths and plan your Drug Discovery and managing your network of contacts is critical to your experience. This year’s learning paths are: success. We invite you join us at our ECP speed networking event at ELRIG Drug Discovery 2019, Europe’s largest free to attend Drug Discovery conference • Speed meet 1:1 with selected representatives across the drug discovery community, including pharma, biotech, CROs, non-for profit and more Non-Small Cancer Neuroscience • Learn how to network effectively Molecule • Increase your awareness of roles and career paths Approaches in industry, academia and beyond • Expand your list of contacts and potential future employers • Open new doors to an exciting future

#ELRIG Drug Discovery 2019 Learning Paths

Non-Small Molecule Approaches Cancer Neuroscience 5 Nov 11:00 - 11:30 5 Nov 11:00 - 11:30 5 Nov 11:30 - 12:00 Room 3B: Room 3B: Room 3A: Accelerating drug discovery for Structure-based PROTAC design Structure-based PROTAC design glioblastoma: the convergence of for drugging undruggable for drugging undruggable patient derived models, CRISPR cancer targets cancer targets engineering and phenotypic screening Professor Alessio Ciulli Professor Alessio Ciulli Professor Steven Pollard (University of Dundee) (University of Dundee) (University of Edinburgh) 5 Nov 11:30 - 12:00 5 Nov 14:00 - 14:30 6 Nov 14:00 - 14:30 Room 3B: Room 3B: Hall 1C: Diverse binding modes for a single interface: a case study in de novo Chemical targeting of deubiquitinating GABAA Receptor Subtype Selective cyclic peptide binding to the BET enzymes Compounds – Where Are We Now? bromodomains for cancer therapy Professor John Atack Louise Walport Sara Buhrlage (Medicines Discovery Institute) (The Francis Crick Institute/ (Dana-Farber Cancer Institute) Imperial College London) 5 Nov 16:00 - 16:30 5 Nov 14:45 - 15:15 5 Nov 16:00 - 16:30 Hall 1B: Room 3A: Room 3B: Using structural information to aid 3D imaging reveals effective in-silico therapeutic design in the era of killing of breast tumor organoids Activity-Based Analyses of immunoglobulin repertoire sequencing by engineered T cells Ubiquitin E3 Ligases Professor Charlotte Deane at a single cell level Satpal Virdee (Department of Statistics, Florijn Dekkers (University of Dundee) University of Oxford) (Princess Máxima Centre) 5 Nov 16:30 - 17:00 6 Nov 11:05 - 16:15 5 Nov 16:30 - 17:00 Room 3B: Hall 1C: Hall 1C: Understanding and Manipulating Cancer Research UK Translational Neuroscience Protein-Protein Interactions Using are hosting a full track for Ion Channels Chemical Biology Approaches Oncology in Drug Discovery John Hutchison David Andrews on day 2 of the conference (Autifony) (AstraZeneca) 6 Nov 14:30 - 15:00 Room 3B: Disease progression in neurodegeneration: unravelling novel biomarkers and therapeutic targets in amyotrophic lateral sclerosis Andrea Malaspina (Blizard Institute, Queen Margaret University, London) 6 Nov 15:15 - 15:45 Room 3A:

Nanoanalytics and imaging methods in Parkinson Disease Matthias Lauer (F. Hoffmann - La Roche Ltd)

#ELRIG Drug Discovery 2019 Workshops discovery projects will be reviewed. Further updates will include the evolution of immune cell killing assays looking at enhanced data analytics and tumour- spheroid invasion analyses. Interactive discussions will be encouraged to explore how live-cell analysis is best Brooks Life Sciences and Titian Software aligned with discovery project requirements and how Workshop: Increase sample processing they can be further developed to address unmet need. efficiency and protect sample integrity with full The workshop is targeted toward researchers with data visibility and inventory management general interest in translational cell models, cell-based assays, cancer biology and immunology, including Tuesday 5th November current and prospective users. 11:00 - 12:00 Room 11A Agenda 11:00 – 11:05 Welcome & introductions Modern day drug discovery and biobanking applications Nicola Bevan (Sartorius) involving both biological and compound samples, often 11:05 – 11:35 Driving preclinical bioscience using iQue requiring automated temperature-controlled storage to Screener and IncuCyte platforms protect sample integrity and improve the efficiency of Adam Peall (Sygnature Discovery) sample processing. These systems protect the chain of condition, identity and custody of sample collections 11:35 – 12:05 Use of combined iQue/IncuCyte workflows, enhanced data analytics and 3D invasion but any connected sample data in a LIMS or Inventory Nicola Bevan (Sartorius) Management system is usually separately managed. 12:05 – 12:10 Concluding remarks In this workshop we will discuss the benefits of a combined inventory management system that controls sample ordering and integrates directly with automated storage and other equipment to track the inventory to track location, temperature and sample meta data in one central system. British Society of Nanomedicine Workshop: Presenters: Enhancing therapeutics - a nano approach Tuesday 5th November Torsten Haensel 11:00 - 12:30 (Technical Applications Specialist, Brooks Life Sciences) Room 11C Toby Winchester (Automation Product Manager, Titian Software) This workshop, led by The British Society for Nanomedicine, will detail current approaches to enhancing therapeutic efficacy using a nanomedicine approach and is aimed at those interested in recent Sartorius Workshop: Live-cell analysis in developments in research, manufacturing and evaluation of nanomedicines. The British Society for combination with flow cytometry: Enhancing Nanomedicine is the UK advocate for the development biological insight and application of nanomedicines across academic and Tuesday 5th November industrial sectors, bringing together and coalescing this 11:00 - 12:20 continually growing field. The workshop is designed for Room 11B new entrants to the nanomedicine field, delivering critical knowledge in a number of the key areas. To enable a greater understanding of disease and Agenda potential therapy, researchers are seeking more translational assays to better describe the clinical 11:00 – 11:15 Welcome & BSNM & nanomedicine overview situation. To meet these requirements has resulted in Andrew Owen (Liverpool University) an increase in model complexity with the introduction 11:15 – 11:35 Developing exosomes and antibody drug of advanced co-culture models in both 2D and 3D. To conjugates for cancer therapy compliment this increased complexity has been the Steve Conlan (Swansea University) demand to extract deeper content from these models, 11:35 – 11:55 Long Acting In Situ Forming Drug Delivery whilst maintaining throughput and ease of use. using Responsive Nanogels Tom McDonald (Liverpool University) In this workshop, we will discuss the latest developments 11:55 – 12:15 Automation leads to accelerated optimization in live-cell analysis and how this can be combined of lipid nanoparticles for mRNA delivery with flow cytometry readouts to enhance biological Kristina Friis (AstraZeneca) understanding. Through a CRO end-user case study 11:15 - 12:30 Open discussion of industry – academia presentation, the use of these workflows in therapeutic partnerships for translational nanomedicine

#ELRIG Drug Discovery 2019 Workshops

Beckman Coulter Life Sciences & Labcyte SiLA Workshop: Simplification in the laboratory: Inc Workshop: How Echo® Acoustic Liquid how the next generation of robotics will help you Handling Can Improve Your Drug Discovery in the lab Workflows Wednesday 6th November Tuesday 5th November 09:00 – 12:30 14:00 - 15:00 Room 11C Room 11A While the mainstay of laboratory has been the liquid Presenter: handler, recent developments in robotics are emerging John Lesnick (Labcyte Inc.) from other industries. These have led to off-loading of complex and demanding tasks onto the robot promoting A greater emphasis on looking back will provide fruitful operators to supervisory roles. This workshop will direction toward discovering the drugs of the future. showcase some of the recent progress and thinking in Acoustic liquid handling is well established at the head robotics for the lab, to improve productivity, quality and of traditional drug discovery funnels / pipelines through innovation. sample management and screening. Implementing acoustic liquid handling toward target identification, Agenda validation and precision medicine can enable learning 09:00 – 09:10 Welcome & Introduction from the design, build, test cycle of drug discovery. Patrick Courtney (Director, SiLA) 09:10 – 09:30 Vision: How to load the dice when approaching innovation with Robotics David Swan (Robotics & Autonomous Charles River Laboratories Workshop: Lead,Tharsus Group UK) Navigating your journey from HTS to MOA 09:30 – 09:50 Application: How will a robot perceive, reason and act at a chemistry lab? A Tuesday 5th November perspective of embodied AI 16:00 - 17:00 Shan Luo (Dept. Computer Science, Room 11A Liverpool University) Learn how to achieve your goals using a collaborative 09:50 - 10:10 Technology: Benefits of mobile robots process, innovative science and robust technology & on-demand automation in R&D labs platforms. Oskari Vinko (Unitelabs, Basel) 10:10 - 10:30 Discussion panel: Agenda Automation in the lab 16:00 – 16:20 Delivering HTS campaigns 10:30 - 11:00 COFFEE collaboratively 11:00 - 11:20 User view: Revolutionising Bench David Cronk, Mark Wigglesworth Formulation in the Manual Laboratory (AstraZeneca) & Philip Kelly (Charles Mark Auty (Unilever / MIF Liverpool) River Laboratories) & Richard Willingham (Applied 16:20 – 16:35 Phenotypic Screening and Compound Scientific Technologies) Capture Mass Spectrometry 11:20 - 11:40 Technology: New grippers for old Marta Stebbeds & Diarmuid Kenny plates (Charles River Laboratories) Michael Köppl (i-gripper Germany) 16:35 – 16:45 Biochemical Mechanism of Action 11:40 - 12:00 Technology: When Remote David Whalley (Charles River Manipulation Meets Pharma Laboratories) Radhika Gudipati (Shadow Robot) 16:45 - 17:00 Q & A’s 12:00 - 12:20 Discussion panel: Connecting it all together 12:20 - 12:30 Summing up & workshop close

#ELRIG Drug Discovery 2019 Workshops

PAA Workshop: High Value Research with Low Alderley Park Accelerator Workshop: A new Cost Automation shared-risk partnership model at Alderley Wednesday 6th November Park for developing and commercialising 11:00 – 12:00 oncology innovations (Academia, Industry, Room 11A SMEs, Specialist CROs, Incubator/Accelerator) Agenda Wednesday 6th November 11:00 – 11:15 Welcome & Introduction 15:00 – 16:00 Malcolm Crook Room 11B (Technical Director PAA) Developing and commercialising new oncology 11:15 – 11:30 Drug Discovery with Hidex plate medicines, biomarkers and models requires a multi- imager & S-LAB plate handler disciplinary, collaborative approach. At Alderley Park, Trevor Askwith we are developing a novel, shared-risk, collaborative (UCL School of Pharmacy) national partnership across Academia, Industry, 11:30 – 11:35 Q & A’s Specialist CROs, SMEs and the Alderley Park Incubator/ Accelerator to identify, de-risk and accelerate the 11:35 - 11:50 Using flow cytometry and automation commercialisation of new therapies and technologies Farah Mughal (Research Project that will improve outcomes for cancer patients in the UK. Specialist, Dept of Biochemistry, University of Liverpool) & Srijan Jindral (University of Manchester) 11:50 - 11:55 Q & A’s 11:55 - 12:00 Workshop close Malcolm Crook (Technical Director PAA)

Drug Discovery 2019 Training Zone

In assossication with:

Tuesday 5th November Wednesday 6th November Cerebral Organoids Cerebral Organoids

Listen to a virtual lecture by Dr Madeline Lancaster Listen to a virtual lecture by Dr Madeline Lancaster (University of Cambridge), giving an overview of brain (University of Cambridge), giving an overview of brain development and an introduction to cerebral organoids. development and an introduction to cerebral organoids. This lecture will be repeated throughout the day at the This lecture will be repeated throughout the day at the following times: following times: 10:05-10:50 10:20-10:40 12:30-14:00 12:50-14:00 15:30-16:00 CRISPR Basics CRISPR Basics Come and listen to our course instructors give an Come and listen to our course instructors virtual lecture, overview of the CRISPR basics. Oliver will introduce giving an overview of the CRISPR basics. CRISPR and Ben will give an introduction to genetically modified mouse models. 12:00-12:30 Introduction to CRISPR Dr Oliver Baker (King’s College London) 11:00-11:50 Introduction to CRISPR & genetically modified mouse models. 14:45-15:15 Introduction to genetically modified

mouse models. Dr Oliver Baker (King’s College London) Dr Ben Davis (University of Oxford) & Dr Ben Davis (University of Oxford)

#ELRIG Track Summary:

Platinum Sponsor track:

Cellular Models of Disease Tuesday 5 November 2019: Room 3A Session Chairs: Paul Andrews (National Phenotypic Screening Centre) & Robert Vries (Hubrecht Organoid Technology)

High attrition rates in drug development, need new approaches to therapeutic discovery, and we especially need preclinical models that faithfully represent patients. The identification of adult stem cells and methods to grow them into so called ‘organoids’, as well as directed differentiation of embryonic stem cells, patient-derived iPSC technology and precision genome engineering have transformed our ability to generate myriad cell types in both the diseased and healthy states and recapitulate at least some aspects of disease in vitro. Recent studies have shown that these patient derived models are directly representing the clinical responses of the associated patients. In addition, the advent of 3D culture in vitro is now opening up the possibility of near-physiological tissue organisation that increasingly is resembling other aspects of the native function. These new models represent a powerful in vitro platform for preclinical drug discovery and validation, as well as finally allowing the long-term promise of personalized medicine, topics which will be discussed in this session.

08:00 - 08:45 REGISTRATION 08:45 - 08:55 ELRIG Annual Review, Steve Rees (ELRIG Chairman) 08:55 - 09:05 Early Career Professionals Overview, Del Trezise (ELRIG ECP Workgroup Leader) 09:05 - 09:15 Conference & Plenary Keynote Introduction, Katy Kettleborough (LifeArc) 09:15 - 10:05 PLENARY KEYNOTE: Turning science into medicine: Hot trends and the business landscape Mene Pangalos (AstraZeneca) 10:05 - 10:50 COFFEE 10:50 - 11:00 Session Chairs Introduction Paul Andrews (National Phenotypic Screening Centre) & Robert Vries (Hubrecht Organoid Technology) 11:00 - 11:30 What goes around comes around in drug discovery: from organs to targets and back again Paul Andrews (National Phenotypic Screening Centre) 11:30 - 12:00 Accelerating drug discovery for glioblastoma: the convergence of patient derived models, CRISPR engineering and phenotypic screening Professor Steven Pollard (University of Edinburgh) 12:00 - 12:30 PLATINUM SPONSOR PRESENTATION: Automation meets cell separation: primary cells for drug discovery assays Lotta Räty (Miltenyi Biotec Ltd) 12:30 - 14:00 LUNCH & POSTERS 14:00 - 14:30 Organoids: A Patient in the lab Robert Vries (Hubrecht Organoid Technology) 14:30 - 14:45 Poster Spotlight: Morphometric imaging of organoids for toxicology & assessment of therapeutic efficacy,Brent Ryan (National Physical Laboratory) 14:45 - 15:15 3D imaging reveals effective killing of breast tumor organoids by engineered T cells at a single cell level Florijn Dekkers (Princess Máxima Centre) 15:15 - 15:30 Poster Spotlight: Morphometric imaging of organoids for toxicology and assessment of therapeutic efficacy, James Noble (National Physical Laboratory) 15:30 - 16:00 COFFEE 16:00 - 16:30 Reducing attrition in drug discovery through the use of human translational cellular models Wendy Rowan (GlaxoSmithKline) 16:30 - 17:00 CRISPR/Cas-assisted genetics in intestinal organoids Bon-Kyoung Koo (IMBA - Institute of Molecular Biotechnology of Austrian Academy of Sciences) 17:00 - 19:00 DRINKS RECEPTION & POSTERS

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’ #ELRIG Track Summary:

Track Sponsor:

Chemical biology – re-defining target tractability and therapeutic class Tuesday 5 November 2019: Room 3B Session Chairs: Marcus Bantscheff (Cellzome A GSK company) & Satpal Virdee, (University of Dundee)

In recent years chemical biology approaches have re-defined therapeutic class and chemical tractability of proteins. Notably, event-driven pharmacology and novel classes of therapeutics offer great promise for targets previously considered undruggable. In this session exciting new concepts in chemical biology and opportunities for drug discovery with tangible potential to improve patient health will be discussed.

08:00 - 08:45 REGISTRATION 08:45 - 08:55 ELRIG Annual Review, Steve Rees (ELRIG Chairman) 08:55 - 09:05 Early Career Professionals Overview, Del Trezise (ELRIG ECP Workgroup Leader) 09:05 - 09:15 Conference & Plenary Keynote Introduction, Katy Kettleborough (LifeArc) 09:15 - 10:05 PLENARY KEYNOTE: Turning science into medicine: Hot trends and the business landscape Mene Pangalos (AstraZeneca) 10:05 - 10:50 COFFEE 10:50 - 11:00 Session Chairs Introduction, Marcus Bantscheff (Cellzome A GSK company) & Satpal Virdee, (University of Dundee) 11:00 - 11:30 Structure-based PROTAC design for drugging undruggable cancer targets Professor Alessio Ciulli (University of Dundee) 11:30 - 12:00 Diverse binding modes for a single interface: a case study in de novo cyclic peptide binding to the BET bromodomains Louise Walport (The Francis Crick Institute/Imperial College London) 12:00 - 12:15 Poster Spotlight: LifeArc Index Set: Utility for assessing target tractability and performance in a phenotypic screen, Afrah Sattikar (LifeArc) 12:15 - 12:20 Technology Spotlight: Diarmuid Kenny (Charles River Laboratories) 12:20 - 12:25 Technology Spotlight: Craig Malcolm (Promega UK Ltd) 12:25 - 12:30 Technology Spotlight: Carol Austin (Eurofins Discovery) 12:30 - 14:00 LUNCH & POSTERS 14:00 - 14:30 Chemical targeting of deubiquitinating enzymes for cancer therapy Sara Buhrlage (Dana-Farber Cancer Institute) 14:30 - 14:45 Poster Spotlight: Development of affinity and fluorescent probes to elucidate the mechanism of small molecule modulators of neurogenesis, Rachel Sim (University of Oxford) 14:45 - 15:15 Towards Next Generation Chemical Probes Keriann Backus (UCLA) 15:15 - 15:20 Technology Spotlight: Devin Donnelly (Beckman Coulter Life Sciences & Labcyte Inc.) 15:20 - 15:25 Technology Spotlight: Hugo Viana (Merck) 15:25 - 15:30 Technology Spotlight: Louise Affleck (Cisbio)

15:30 - 16:00 COFFEE 16:00 - 16:30 Activity-Based Analyses of Ubiquitin E3 Ligases Satpal Virdee (University of Dundee) 16:30 - 17:00 Understanding and Manipulating Protein-Protein Interactions Using Chemical Biology Approaches David Andrews (AstraZeneca) 17:00 - 19:00 DRINKS RECEPTION & POSTERS

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’ #ELRIG Track Summary

Big Data and Artificial Intelligence Tuesday 5 November 2019: Hall 1B

Session Chairs: Ola Engkvist (AstraZeneca) & Hugo Ceulemans (Janssen Pharmaceutica)

Artificial Intelligence (AI) is now being applied everywhere including drug discovery. In this session we would like to give the audience a sense of what is going on in applying AI and machine learning (ML) in drug discovery by covering several important aspects. The background and historical development of ML and AI in drug discovery will be presented. We will also take a look at the most important ingredient to successfully apply ML and AI in drug discovery project, namely the data and how it can be integrated. Applying ML to large datasets is an important topic that pushes the current machine learning algorithms to the limit. Another important topic to be covered is the integration of ML/AI with automation and the sizeable synergy effects when combining them. Finally, application of deep learning in drug design has now become common, so it is time to hear from a medicinal chemist expert if there has been any real impact on the drug design process or if it just has been another hype.

08:00 - 08:45 REGISTRATION 08:45 - 08:55 ELRIG Annual Review, Steve Rees (ELRIG Chairman) 08:55 -09:05 Early Career Professionals Overview, Del Trezise (ELRIG ECP Work group Leader) 09:05 - 09:15 Conference & Plenary Keynote Introduction, Katy Kettleborough (LifeArc) 09:15 - 10:05 PLENARY KEYNOTE: Turning science into medicine: Hot trends and the business landscape Mene Pangalos (AstraZeneca) 10:05 - 10:50 COFFEE 10:50 - 11:00 Session Chairs Introduction Ola Engkvist (AstraZeneca) & Hugo Ceulemans (Janssen Pharmaceutica) 11:00 - 11:30 Artificial Intelligence: the story so far and the next chapter for drug discovery Sam Genway (Tessella) 11:30 - 12:00 Development of FAIR data methods in Life Science and Drug Discovery research Philip Gribbon (Fraunhofer IME ScreeningPort) 12:00 - 12:15 Poster Spotlight: Discovering Novel Therapeutic Targets Using Large Biomedical Knowledge Graphs Arwa Raies (European Bioinformatics Institute (EMBL-EBI)) 12:15 - 12:20 Technology Spotlight: Evelyne Ploquin (Thermo Fisher Scientific) 12:20 - 12:25 Technology Spotlight: Cameron Scott (Genedata AG) 12:25 - 12:30 Technology Spotlight: Jonathan Agbenyega (CAS) 12:30 - 14:00 LUNCH & POSTERS 14:00 - 14:30 Embedding Machine Learning into Medicinal Chemistry – Application of Neural Networks in Real Life Drug Discovery Projects Werngard Czechtizky (AstraZeneca) 14:30 - 14:45 Poster Spotlight: Expression Data Integration: Advancing Immuno-Oncology Target Discovery Frank Staubli (Nebion AG) 14:45 - 15:15 Data Science and AI approaches to Drug Target Validation and repurposing Professor Michael Barnes (Centre for Translational Bioinformatics, William Harvey Research Institute, Queen Mary University of London) 15:15 - 15:20 Technology Spotlight: Stina Lundgren (Pelago Bioscience AB) 15:20 - 15:25 Technology Spotlight: Mark Wigglesworth (AstraZeneca, SLAS) 15:25 - 15:30 Technology Spotlight: Mark Graham (GE Healthcare) 15:30 - 16:00 COFFEE 16:00 - 16:30 Deep Generative Models for 3D Compound Design Professor Charlotte Deane (Department of Statistics, University of Oxford) 16:30 - 17:00 AI(d) in navigating small molecule space Hugo Ceulemans (Janssen Pharmaceutica) 17:00 - 19:00 DRINKS RECEPTION & POSTERS

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’ #ELRIG Track Summary

Track Sponsor: Targeting Ion Channels for Drug Discovery Tuesday 5 November 2019: Hall 1C Session Chairs: Sarah Nickolls (GlaxoSmithKline) & David Kendall (Pharmnovo)

Hosted by:

Drugs targeting ion channels are an important component of many medicine cabinets, but over the past 10-15 years active programs targeting ion channels in the pharmaceutical industry have fallen and a perception may exist that these are difficult proteins to drug. However, significant progress in understanding ion channel pharmacology and structure is being made, which leads us to suggest that this target class is currently being under exploited. Therefore, in this symposium we will look at some of the recent progress in targeting ligand and voltage gated ion channels in disease.

08:00 - 08:45 REGISTRATION 08:45 - 08:55 ELRIG Annual Review, Steve Rees (ELRIG Chairman) 08:55 - 09:05 Early Career Professionals Overview, Del Trezise (ELRIG ECP Work group Leader) 09:05 - 09:15 Conference & Plenary Keynote Introduction, Katy Kettleborough (LifeArc) 09:15 - 10:05 PLENARY KEYNOTE: Turning science into medicine: Hot trends and the business landscape Mene Pangalos (AstraZeneca) 10:05 - 10:50 COFFEE 10:50 - 11:00 Session Chairs Introduction Sarah Nickolls (GlaxoSmithKline) & David Kendall (Pharmnovo) 11:00 - 11:30 Activation of mechanosensitive TREK potassium channels – a therapeutic strategy for the treatment of pain Professor Alistair Mathie (University of Kent) 11:30 - 12:00 Screening for activators of K2P channels - A target class approach to identify novel analgesics Paul Wright (LifeArc) 12:00 - 12:10 Poster Spotlight: A Higher-Throughput Approach to Investigate Cardiac Contractility In Vitro Under Physiological Mechanical Conditions Matthias Gossmann (innoVitro GmbH) 12:10 - 12:30 INDUSTRY INSIDER PRESENTATION: Potent and selective state-dependent Cav2.2 calcium channel modulators with efficacy in preclinical pain models and human tissue Marc Rogers (Metrion Biosciences Ltd) 12:30 - 14:00 LUNCH & POSTERS 14:00 - 14:30 GABAA Receptor Subtype Selective Compounds – Where Are We Now? Professor John Atack (Medicines Discovery Institute) 14:30 - 14:45 Poster Spotlight: Ligand-gated ion channels involved in pain pathways: An automated patch clamp study Alison Obergrussberger (Nanion Technologies GmbH) 14:45 - 15:15 Targeting voltage-gated calcium channels in disease Professor Gary Stephens (University of Reading) 15:15 - 15:20 Technology Spotlight: Juha Kammonen (Charles River Laboratories) 15:20 - 15:25 Technology Spotlight: Dan Lord (Formulatrix) 15:25 - 15:30 Technology Spotlight: Joe Lackey (LGC) 15:30 - 16:00 COFFEE 16:00 - 16:30 A story of collaboration: Ion Channels for Drug Discovery Kelly Gatfield (GlaxoSmithKline) 16:30 - 17:00 Translational Neuroscience for Ion Channels John Hutchison (Autifony) 17:00 - 19:00 DRINKS RECEPTION & POSTERS

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’ #ELRIG Session Summary:

Molecular and Cellular Imaging Wednesday 6 November 2019: Room 3A Session Chair: Michael Hennig (leadXpro AG)

Visualization of biological structures has been of great impact to the understanding of biological mechanisms including drug action. This session covers a number of cutting-edge technologies to facilitate the structure determination from small molecules (chemical compounds by electron diffraction of nano-crystals) to large biological complexes with drug candidates investigated by X-ray crystallography and cryo-Electron Microscopy. Time resolved and multi-conformation analysis gives insight into drug binding and associated molecular dynamics visualizing pharmacological response. Extension of the methods to the imaging of cells by cryo-EM tomography and Mass spectroscopy will give exciting new perspectives for the understanding of diseases.

08:00 - 09:00 REGISTRATION 09:00 - 09:10 Welcome & Introduction to Plenary Keynote, Tim Hammonds (Cancer Research UK) 09:10 - 10:00 PLENARY KEYNOTE: Tackling diseases of ageing – the application of new approaches in drug discovery and development Dr Fiona Marshall (MSD) 10:00 - 10:20 INDUSTRY INSIDER PRESENTATION: Nurturing effective translation Melanie Lee (LifeArc) 10:20 - 11:00 COFFEE 11:00 - 11:10 Session Chairs Introduction Michael Hennig (leadXpro AG) 11:10 - 11:40 CRYO-EM and X-RAY free electron laser enabled structure based drug discovery on challenging mem- brane protein targets Michael Hennig (leadXpro AG) 11:40 - 11:45 Technology Spotlight: Suzanne Riches (Nexcelom) 11:45 - 11:50 Technology Spotlight: Antoine Fouillet (BioTek Instruments Ltd) 11:50 - 12:20 Electron diffraction of 3D protein crystals Emma Beale (Diamond Light Source Ltd) 12:20 - 12:40 ELRIG ECP IMPACT AWARD WINNER PRESENTATION: Drug discovery data on demand Thomas Fleming (Arctoris) 12:40 - 12:45 Technology Spotlight: Corné Swart (Cellbox Solutions) 12:45 - 12:50 Technology Spotlight: Alistair Robertson (Tecan UK Ltd) 12:50 - 14:00 LUNCH & POSTERS 14:00 - 14:30 Novel opportunities for targeting metabolic regulation from imaging macromolecular assemblies Timm Maier (Biozentrum, University of Basel) 14:30 - 15:00 Mass Spectrometry - A Useful Addendum for Multimodal Imaging Pipelines? Martina Marchetti-Deschmann (TU Wien, Institute of Chemical Technologies and Analytics) 15:00 - 15:15 Poster Spotlight: Automated imaging and analysis of collective cell migration Hiren Patel (CytoSMART Technologies B.V.) 15:15 - 15:45 Nanoanalytics and imaging methods in Parkinson Disease Matthias Lauer (F. Hoffmann - La Roche Ltd) 15:45 - 16:15 Cell geometry modulates the activation of fibroblasts in engineered 3D tumor microenvironments Saradha Venkatachalapathy (Mechanobiology Institute, National University of Singapore) 16:15 - 16:30 CONFERENCE CLOSE - Tim Hammonds (Cancer Research UK)

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’ #ELRIG Session Summary:

Biomarker Strategies in Drug Discovery Wednesday 6 November 2019: Room 3B Session Chairs: Sally Price (Medicines Discovery Catapult) & Ian Pike (Ian Pike Consulting)

The use of clinical biomarkers has grown exponentially since they were first employed in the 1970s. The sequencing of the human genome and development of omics technologies have significantly accelerated the development and adoption of biomarkers in drug discovery and development, as well as clinical decision making. Biomarkers for precision medicine in oncology has probably seen the greatest benefit from this technological innovation with new developments continuing to push boundaries. Biomarkers in other disease areas are now following behind the precedent set in oncology. These are facing different challenges but have significant potential to facilitate better treatment options for patients. This session will discuss how appropriate, well validated, biomarkers will drive a reduction in drug attrition in all therapeutic areas over the next few decades.

08:00 - 09:00 REGISTRATION 09:00 - 09:10 Welcome & Plenary Keynote Introduction, Tim Hammonds (Cancer Research UK) 09:10 - 10:00 PLENARY KEYNOTE: Tackling diseases of ageing – the application of new approaches in drug discovery and development Dr Fiona Marshall (MSD) 10:00 - 10:20 INDUSTRY INSIDER PRESENTATION: Nurturing effective translation Melanie Lee (LifeArc) 10:20 - 11:00 COFFEE 11:00 - 11:10 Session Chairs Introduction Sally Price (Medicines Discovery Catapult) & Ian Pike (Ian Pike Consulting) 11:10 - 11:40 Label-Free Imaging and its many applications Peter O’Toole (University of York) 11:40 - 11:45 Technology Spotlight: Catherine Wark (BMG Labtech Ltd) 11:45 - 11:50 Technology Spotlight: Stephan Kaizik (Bio Rad) 11:50 - 12:20 Supporting pathology with multimodal molecular mass spectrometry imaging: Case studies in compound biodistribution, efficacy and safety Gregory Hamm (AstraZeneca) 12:20 - 12:35 Poster Spotlight: The Cellular Thermal Shift Assay in drug discovery: how CETSA ® MS identify targets, off-targets and biomarkers in live cells, Isabel M Caballero (Pelago Bioscience AB) 12:35 - 12:40 Technology Spotlight: Jennifer Birtwell (Hamilton Bonaduz AG) 12:40 - 12:45 Technology Spotlight: Lucy Farmer (LabLogic Systems Limited) 12:45 - 12:50 Technology Spotlight: Zoe Nilsson (Sphere Fluidics Limited) 12:50 - 14:00 LUNCH & POSTERS 14:00 - 14:30 Biomarker Strategies in Drug Discovery: Can we Reduce Attrition and Streamline Development of Novel Anti-Fibrotics? Sally Price (Medicines Discovery Catapult) & Simon Cruwys (TherapeutAix) 14:30 - 15:00 Disease progression in neurodegeneration: Unravelling novel biomarkers and therapeutic targets in amyotrophic lateral sclerosis Andrea Malaspina (Blizard Institute, Queen Margaret University, London) 15:00 - 15:15 Poster Spotlight: Immuno-Oncology Drug Testing in Patient-Derived Microtumor/Immune Cell Models: The Added Value of Protein Profiling, Christoph Sachse (NMI TT Pharmaservices) 15:15 - 15:45 The Modern Proteomics Continuum for Biomarker Discovery, Validation and Implementation in Drug Discovery Ian Pike (Ian Pike Consulting) 15:45 - 16:15 High sensitivity immunoassays for translational biomarker assessments: from mice to men Chantal Bazenet (Evotec) 16:15 - 16:30 CONFERENCE CLOSE - Tim Hammonds (Cancer Research UK)

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’ #ELRIG Session Summary:

Platinum Sponsor track: Hit Finding Strategies Wednesday 6 November 2019: Hall 1B Session Chairs: Philip Gribbon (Fraunhofer IME Screening Port) & Rosemary Burke (The Institute of Cancer Research)

The process of identifying small molecule hits which are suitable for subsequent optimisation into leads and eventually candidates is a critical stage of the drug discovery workflow. In this session, we will hear from industrial and academic experts on their organisations’ approaches taken to find high quality starting points for a range of biochemical targets and phenotypic readouts. Talks will cover strategies and case studies, including the use of fragment-based and biophysical readouts, experiences of new and enabling technologies, as well the systematic use of phenotypic assay formats utilising iPSC derived cellular models of disease.

08:00 - 09:00 REGISTRATION 09:00 - 09:10 Welcome & Plenary Keynote Introduction, Tim Hammonds (Cancer Research UK) 09:10 - 10:00 PLENARY KEYNOTE: Tackling diseases of ageing – the application of new approaches in drug discovery and development Dr Fiona Marshall (MSD) 10:00 - 10:20 INDUSTRY INSIDER PRESENTATION: Nurturing effective translation Melanie Lee (LifeArc) 10:20 - 11:00 COFFEE 11:00 - 11:10 Session Chairs Introduction Philip Gribbon (Fraunhofer IME Screening Port) & Rosemary Burke (The Institute of Cancer Research) 11:10 - 11:40 How small can you go? Crystallographic screening with ultra-low molecular weight fragments to guide drug design Tom Davies (Astex Pharmaceuticals) 11:40 - 11:50 Poster Spotlight: An enabling label-free platform for RNA drug discovery using SAMDI mass spectrometry, Zachary Gurard-Levin (SAMDI Tech, Inc.) 11:50 - 12:20 Application of Sosei Heptares GPCR StaR® platform for Structure Based Drug Design & Hit Identification Greg Osborne (Sosei Heptares) 12:20 - 12:50 PLATINUM SPONSOR PRESENTATION: Fragment-based hit-finding strategy reveals novel chemistry against three cancer targets Jana Wolf (NanoTemper Technologies) 12:50 - 14:00 LUNCH & POSTERS 14:00 - 14:30 THOUGHT LEADER SPONSOR PRESENTATION: Enabling Success in Lead Identification Colin Sambrook Smith (Sygnature Discovery) 14:30 - 15:00 Hit Identification, how to start a drug discovery project right Guillaume Mondesert (Evotec) 15:00 - 15:15 Poster Spotlight: High throughput small molecule screening for inducers of epicardial cell EMT after myocardial infarction, Sophia Malandraki-Miller (University of Oxford) 15:15 - 15:45 Finding inhibitors of transcription factor activation with phenotypic screens Paul Clarke (Institute of Cancer Research) 15:45 - 16:15 Hit finding to series validation - where are the bottlenecks? Professor David Gray (University of Dundee) 16:15 - 16:30 CONFERENCE CLOSE - Tim Hammonds (Cancer Research UK)

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’ #ELRIG Session Summary:

Oncology Drug Discovery Wednesday 6 November 2019: Hall 1C Session Chairs: Heather McKinnon (Beatson) & Graeme Walker (Cancer Research UK)

Hosted by:

CRUK is a leader in funding cancer research across the UK, supporting basic research to unravel the mechanisms by which cancer cells survive and grow. To ensure this science is rapidly and effectively translated into new treatments for patients, CRUK also funds a number of Drug Discovery Units (DDUs) to work closely with basic scientists within their institutes and across the CRUK network. These groups provide industry standard research covering all stages of the drug discovery process from early validation studies, through hit finding, lead optimisation and into clinical development. CRUK currently has more than 30 agents in pre-clinical and clinical development and six drugs already on the market being used to treat patients. In this track you will hear about a number of the projects currently being prosecuted by the drug discovery groups, taking both small molecule and antibody approaches. You will also gain an insight into the type of technology that enables drug discovery today to advance on some of the really challenging targets that are likely to have a substantial impact on cancer therapy.

08:00 - 09:00 REGISTRATION 09:00 - 09:10 Welcome & Plenary Keynote Introduction, Tim Hammonds (Cancer Research UK) 09:10 - 10:00 PLENARY KEYNOTE: Tackling diseases of ageing – the application of new approaches in drug discovery and development Dr Fiona Marshall (MSD) 10:00 - 10:20 INDUSTRY INSIDER PRESENTATION: Nurturing effective translation Melanie Lee (LifeArc) 10:20 - 11:00 COFFEE 11:00 - 11:05 Session Chairs Introduction Heather McKinnon (The Beatson Institute for Cancer Research) & Graeme Walker (Cancer Research UK Manchester Institute) 11:05 - 11:45 Title: Innovative cancer drug discovery: Progress, opportunities and future challenges Professor Paul Workman (The Institute of Cancer Research, London) 11:45 - 11:50 Technology Spotlight: Nirmal Perera (LGC - ATCC) 11:50 - 12:20 The Power of One: Discovery of the first selective and non-covalent small molecule inhibitors of DNMT1 Ali Raoof (Cancer Research UK Manchester Institute) 12:20 - 12:25 Technology Spotlight: Sharon Barnard (INTEGRA Bioscience Ltd) 12:25 - 12:50 Cancer Research UK AstraZeneca Antibody Alliance Laboratory: Delivering therapeutic and diagnostic antibodies through collaboration Maria Groves (Cancer Research UK-MedImmune Alliance Laboratory) 12:50 - 14:00 LUNCH & POSTERS 14:00 - 14:30 Innovative drug discovery alliances to maximize patient benefit in Immuno-Oncology Stuart Farrow (CR-UK Therapeutic Discovery Laboratories) 14:30 - 15:00 Structure-based optimisation of isoindolinone MDM2-p53 inhibitors with potent in vivo activity Ian Hardcastle (Newcastle University) 15:00 - 15:15 Poster Spotlight: The Joint AstraZeneca - Cancer Research UK Functional Genomics Centre: Driving Drug Discovery Through Innovation In Functional Genomics Screening David Walter (Cancer Research UK–AstraZeneca Functional Genomics Centre) 15:15 - 15:45 The discovery of Novel Fascin Inhibitors and their potential role in Invasion and Metastasis Stuart Francis (The Beatson Institute for Cancer Research) 15:45 - 16:15 MPS1 inhibitors and the molecular basis for resistance to MPS1 inhibition Rob Van Montfort (The Institute of Cancer Research) 16:15 - 16:30 CONFERENCE CLOSE - Tim Hammonds (Cancer Research UK)

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’ #ELRIG Drug Discovery 2019 Technology Spotlight Titles Tuesday 5th November

Track: Cellular Models of Disease • Automation meets cell separation: primary cells for drug discovery assays, Lotta Räty (Miltenyi Biotec Ltd)

Track: Chemical biology - re-defining target and therapeutic class tractability • Discovery of New Therapeutics through the fusion of small & large molecules, Diarmuid Kenny (Charles River Laboratories) • Measurement of kinase inhibitor target engagement in live-cells & mechanistic analysis of PROTAC-mediated targeted degradation of kinase targets, Craig Malcolm (Promega) • Evolution of Contract Research Organizations to Contract Innovation Organizations? Carol Austin (Eurofins Discovery) • Beckman and Labcyte: Dawning of a new Liquid Handling Era, Devin Donnelly (Beckman Coulter Life Sciences & Labcyte Inc.) • Partial PROTACs for Targeted Protein Degradation, Hugo Viana (Merck) • HTRF Assays for Target Biology identification and Validation in Drug Discovery, Louise Affleck (Cisbio)

Track: Big Data & Artificial Intelligence • On the way to Artificial Intelligence: Feeding data hungry Machine Learning Algorithms using Thermo Scientific Momentum Lab Automation Systems, Evelyne Ploquin (Thermo Fisher Scientific) • Genedata Imagence® - Deep Learning Automates the Analysis of Cell Painting Assays, Cameron Scott (Genedata) • Conquer the Chaos, Jonathan Agbenyega (CAS) • Navigate the proteome with CETSA® MS, Stina Lundgren (Pelago) • SLAS’s Growing AIm in Artificial Intelligence and Big Data, Mark Wigglesworth (AstraZeneca, SLAS) • The Evolution of High Content Analysis, Mark Graham (GE Healthcare)

Track: Targeting ion channels for drug discovery • Potent and selective state-dependent Cav2.2 calcium channel modulators with efficacy in preclinical pain models and human tissue, Marc Rogers (Metrion Biosciences) • Realise the full potential of your ion channel targets with Charles River, David Cronk (Charles River Laboratories) • Scaling Organoid Culture using MANTIS ® Liquid Handler: A Case Study with MIT, Dan Lord (Formulatrix) • TRC: Introducing a comprehensive range of high quality research chemical’s and custom synthesis solutions, Joe Lackey (LGC) Wednesday 6th November

Track: Molecular & Cellular Imaging • CellacaTM MX: A novel instrument for high-throughput, high-speed cell counting, concentration, and viability, Suzanne Riches (Nexcelom) • The new wide field of view Cytation 5: from cell counting to complex imaging applications, Antoine Fouillet (BioTek Instruments) • The #CELLBOX - The Live Cell Shipper, Corné Swart (Cellbox Solutions) • Spark Cyto – Live Cell Plate Reader with Real-Time Image Cytometry, Alistair Robertson (Tecan)

Track: Biomarkers Strategies in Drug Discovery • Microplate Reader technology for Biomarker assays and discovery, Catherine Wark (BMG Labtech Ltd) • Bio-Rad Bio-Plex® Multiplex Immunoassay in Biomarker Discovery & Validation, Stephan Kaizik (Bio-Rad Laboratories Ltd) • Vantage: The Power Of Automation, Jennifer Birtwell (Hamilton) • Hidex Sense Multi Technology Microplate Reader and InCellis Samrt Cell Imaging System, Lucy Farmer (Lablogic) • A Revolutionary Platform for Single Cell Analysis in Drug Discovery, Zoe Nilsson (Sphere Fluidics)

Track: Hit Finding Strategies • Fragment-based hit-finding strategy reveals novel chemistry against two cancer targets, Jana Wolf (Nano-Temper)

Track: Oncology Drug Discovery • From bench to bedside: advanced ATCC cancer models for translational cancer research, Nirmal Perera (LGC) • Assist Plus, Sharon Barnard (Integra Bioscience)

#ELRIG ELRIG Events 2020

CRISPR in Research & Drug Discovery 2020 Innovation 2020 From Targets to Therapeutics Therapeutic innovation for the new decade Babraham Institute, Cambridge The KingÕs Centre, Oxford 4 - 5 March 2020 31 March - 1 April 2020

The second CRISPR in Drug Discovery: From The 2020 ELRIG Research & Innovation conference Targets to Therapeutics meeting will be held at will discuss how the most promising new biology is the Babraham Institute, Cambridge, 12th and 13th being identified and explore emerging technologies February 2020. Genome Engineering, including and innovations to enable this science to be zinc-finger nucleases, TALENs and most recently translated into successful therapeutics. The four CRISPR/Cas9, has become a powerful tool in the scientific sessions will address different aspects of drug discovery pipeline. innovation in biology and discovery technologies as we move into a new decade: This meeting will focus on the application of genome engineering to identify novel drug targets • Innovations in structural biology & biophysics through large scale CRISPR based functional genomics studies, developing advanced cellular Examining the prospects for structural biology and and in vivo disease models for target validation, and biophysics in complex and more physiological the pioneering applications in therapeutic genome systems and in supporting the entire discovery editing. A current perspective of the applications of process from target identification through to these rapidly developing technologies with a focus assessment of target engagement on drug discovery applications will be the meeting’s focus. The scientific program for this CRISPR in • The rise of immunology across Discovery Drug Discovery meeting will include: Moving beyond the field of immuno-oncology to explore both the rising interest in immunology- • Large-scale CRISPR functional genomics based targets in other therapeutic areas and studies for drug target identification and highlight the potential of different therapeutic validation modalities. • Application of genome engineering in • Seeking novel drug targets for the Discovery developing biological models of disease pipeline from single cells through to complex in vitro tissue systems and in vivo models Highlighting new technologies that are being

developed alongside new approaches to • Cutting edge CRISPR genome engineering academia-industry collaboration that are technologies and their emerging combining to build a pipeline of new targets for applications drug discovery. • A perspective from technology leaders toward the future therapeutic applications • Good bugs / bad bugs of genome engineering The first part of this session will explore the We aim to bring together the research community biology of the microbiome in health and disease working in the field of genome engineering with and the prospects for microbiome-targeting drug interests in developing and applying the technology therapies. The second part will concentrate on for pharmaceutical research. Join scientists from technical and platform innovations in the field of academia, pharma, biotech, and CRO’s to hear talks antibiotic discovery. given by speakers at the cutting edge of genome engineering, take part in commercial vendor lab- based workshops, network at the exhibition, innovation forum and speakers dinner and gain strategic insights into solutions for increasing the success of drug discovery and development.

#ELRIG ELRIG Events 2020

Drug Cell & Gene Discovery 2020 Therapy 2020 20:20 Vision - enabling discovery of new medicines AstraZeneca, Gothenburg ExCeL, London 6 - 7 May 2020 6 - 7 October 2020

The first ELRIG meeting on Advances in Cell Now in its 14th year, ELRIG’s flagship conference and Gene Therapies will be held on the 6th and Drug Discovery 2020 will take place at ExCeL, 7th of May 2020 at the AstraZeneca R&D site in London. This year’s event will include cutting Gothenburg. This interactive 2-day conference will edge talks and examples of new directions in drug host world leading scientists from academia and discovery. Our scientific programme will feature industry to discuss current and future perspectives over 50 world-class speakers with 6 main session of Cell and Gene Therapies. tracks and 2 plenary keynote speakers. The tracks for 2020 are: Cell and gene therapies are rapidly evolving at a fast pace, revealing many new and exciting therapeutic • Innovations in Chemistry to discover new opportunities not previously amenable to drug medicines discovery. We aim to bring together scientists from • How do we find better Hits that are more likely academia, pharma, biotech, and CRO’s to engage to translate to new therapeutics? with speakers at the cutting edge of developing • New Modalities to treat disease and applying cell and gene therapies. • Multi Omic approaches to deliver new medicines The event will help participants develop a better • Patient relevant models for drug discovery understanding of the field and provide networking Infection opportunities with a range of key experts. Our aim is to create an open and inspiring environment that will foster discussions and the identification In partnership with key academic and charitable of opportunities for collaboration with a scientific groups, we will also run joint disease and biology- program developed around three key focus areas: oriented tracks focusing on the basic sciences that underpin successful drug discovery. • Cell based therapies across disease areas Drug Discovery has become the largest meeting • Recent advances in cancer gene therapies of life sciences industry professionals in the UK. This 2-day event will bring together more than • Therapies for genetic conditions 1200 delegates and over 100 exhibiting companies from around the world who will highlight the latest There will be numerous opportunities to network with ground-breaking research, discuss cutting-edge scientists and researchers from the pharmaceutical, advances in the application of laboratory technology academic and vendor communities throughout the to understand disease biology and to identify novel 2-day conference. The program also includes poster chemical and biological candidate drugs. viewing sessions, a poster snapshot presentation opportunity for select posters, vendor exhibition, To maximize the interaction between delegates speaker’s dinner and tour of the Amazing Journey and exhibitors/sponsors, our programme includes at AstraZeneca. scientific poster sessions, coffee/tea and lunch breaks that are located within the vendor exhibition area and a drinks/networking reception on the first day. The meeting is free-of-charge to all delegates and include complimentary refreshments and lunch. Exhibition spaces are limited so we recommend booking early to ensure a prime location.

#ELRIG ELRIG Events 2020

Pharmaceutical ELRIG Flow Cytometry Networking & Imaging 2020 Events 2020 GlaxoSmithKline, Stevenage Locations across the UK 24 - 25 November 2020 Throughout 2020

The 7th biennial Pharmaceutical Flow Cytometry and Since the launch of ELRIG networking events Imaging meeting will be held at GlaxoSmithKline, at the end of 2016, we have hosted a series of Stevenage, UK. Flow cytometry and imaging are successful meetings at various locations around two powerful technology platforms that enable high- the country. These are short, usually evening content analysis of physiologically-relevant cell sessions, encouraging collaboration between local systems and pre-clinical and clinical biomarkers. scientists from academia and pharma, biotech and Since our first meeting in 2008, we have seen the technology industries. The focus is on developing technology develop and the applications widen solutions for unmet scientific or technical challenges across many areas of industrial and academic drug and to create opportunities through this enhanced discovery and development. This meeting will focus collaboration to engage in a beneficial manner in a on the application of Flow Cytometry and Imaging localised environment. to illuminate biology from the single cell to the patient. The scientific program for this meeting is: Each event has a different theme, and typically involves 2-3 informal presentations by invited • Translational Flow Cytometry and Imaging in speakers whose work is relevant to the theme of Drug Discovery and Development the meeting. This is followed by an opportunity to network over food and drinks. Examining the prospects for structural biology and biophysics in complex and more physiological ELRIG will host six networking events during systems and in supporting the entire discovery 2020. Planned locations are Cambridge, Cheshire, process from target identification through to London, Nottingham, Oxford and Scotland. assessment of target engagement We expect an average of 50 delegates per event, and limit the sponsorship to a maximum of 5 • Novel and Emerging Technologies vendors. Events are held in academic or company Next generation instrumentation, and probe and facilities, to encourage local delegates to “drop in” sensor technology for pharmaceutical research. after work. The cost of a table top for these events is £500 which includes: • Next generation Cytomics in Pharmaceutical • 1m x 0.5m table top exhibition space Research • 5 minute technology spotlight to the entire Exploration of the latest systems approaches, audience utilising functional genomic technologies to link • Logo on programme and web site the genome and proteome to cellular regulation • Participant attendee list and function, for predictive medicine. • All refreshments included

We aim to bring together the research community Provisional 2020 Dates working in the field of flow cytometry and imaging January 2020: BioCity, Scotland with interests in developing and applying the March 2020: Oxford technology for pharmaceutical research. Join May 2020: The Francis Crick Institute, London scientists from pharma, biotech, CROs and academia June 2020: BioCity, Nottingham to hear talks given by speakers at the cutting edge of July 2020: Cambridge cytometry, take part in commercial vendor lab-based November 2020: Alderley Park, Cheshire workshops, network at the exhibition, innovation forum and speakers dinner and gain strategic insights into solutions for increasing the success of drug discovery and development.

#ELRIG Drug Discovery 2019 Sponsors

Platinum Sponsors

Miltenyi Biotec GmbH Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our 30 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has 2,500 employees in 28 countries. www.miltenyibiotec.com

NanoTemper Technologies Our mission at NanoTemper Technologies is to enable everyone to do science that matters by always pushing the limits. We’re focused on making biophysical tools accessible to anyone looking to characterize proteins in any industry. If you need fast, non-stop and highly sensitive affinity-based hit identification and lead validation, or want to measure binding interactions, characterize protein stability or protein quality, let’s talk. www.nanotempertech.com

Thought Leader Sponsor

Sygnature Discovery Sygnature Discovery is a leading drug discovery provider, offering a full range of integrated and single discipline services across biology, in vivo pharmacology, medicinal/computational chemistry, and DMPK/Tox. Since 2011, 30 compounds discovered by Sygnature Scientists have entered preclinical development with 14 advancing to clinical trials. www.sygnaturediscovery.com

Industry Insider Sponsors

LifeArc LifeArc is an independent medical research charity. We advance translation of early science into health care treatments or diagnostics that can be made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. www.lifearc.org

Metrion Biosciences Ltd Metrion Biosciences offers a range of high quality ion channel screening assays on a fee-for-service or collaborative basis. Metrion’s expertise includes in vitro cardiac ion channel safety assays such as hERG, translational native cell and phenotypic assays for neurological and cardiotoxicity testing and a range of ion channel drug discovery services. www.metrionbiosciences.com

#ELRIG Drug Discovery 2019 Sponsors

Gold Sponsors

Beckman Coulter Life Sciences & Labcyte Inc. BMG LABTECH Ltd Brooks Life Science www.beckman.com / www.labcyte.com www.bmglabtech.com www.brookslifesciences.com

INTEGRA Bioscience Ltd Sarstedt Ltd Sartorius Stedim Biotech Tecan UK Ltd www.integra-biosciences.com www.sarstedt.com www.tapbiosystems.com www.tecan.com Silver Sponsors

Eurofins Discovery Hamilton Sales and Service UK Ltd www.eurofinsdiscoveryservices.com www.hamiltoncompany.com

Bronze Sponsors

Astech Projects Ltd LGC - ATCC www.astechprojects.co.uk www.lgcstandards-atcc.org

Bio-Rad Laboratories Ltd Merck www.bio-rad.com www.sigmaaldrich.com/

BioTek Instruments Ltd Nexcelom Bioscience Ltd www.biotek.com www.nexcelom.com

CAS Pelago Bioscience AB www.cas.org www.pelagobio.com

Cisbio Promega UK Ltd www.cisbio.com www.promega.com

Formulatrix, Inc. Sphere Fluidics Ltd www.formulatrix.com www.spherefluidics.com

Genedata AG Thermo Fisher Scientific www.genedata.com/ www.thermoscientific.com screener

LabLogic Systems Ltd www.lablogic.com

Career Partners

GlaxoSmithKline Langton Howarth www.gsk.com/en-gb/careers www.langtonhowarth.co.uk

#ELRIG Drug Discovery 2019 Exhibitors acCELLerate GmbH ChemoMetec Proteome Sciences Plc www.accellerate.me www.chemometec.com www.proteomics.com Admescope Ltd Creoptix AG Reaction Biology Corporation www.admescope.com www.creoptix.com www.reactionbiology.com Analytik Jena AG CytoSMART Technologies B.V. Repositive www.analytik-jena.com www.cytosmart.com www./repositive.io Andrew Alliance Dispendix ReproCELL www.andrewalliance.com www.dispendix.com www.reprocell.com Applied Scientific Technologies UK Ltd Fluidic Analytics RxNet www.appliedst.co.uk www.fluidic.com www.rx-network.com Aptamer Group Limited Fluidigm UK Ltd STEMCELL Technologies www.aptamergroup.co.uk www.fluidigm.com www.stemcell.com Ardigen GC biotech Stratech Scientific Ltd www.ardigen.com www.gcbiotech.com www.stratech.co.uk Aurelia Bioscience Greiner Bio One Synthego www.aureliabio.com www.gbo.com www.synthego.com BioAscent Discovery Ltd Hamamatsu Photonics UK Ltd Taconic www.bioascent.com www.hamamatsu.com www.taconic.com BioIVT HighRes Biosolutions Ltd Tissue Solutions www.bioivt.com www.highresbio.com www.tissue-solutions.com BlueCatBio GmbH I&L Biosystems UK Ltd Titian Software Ltd www.bluecatbio.com www.il-biosystems.com/de-en/ www.titian.co.uk Cambridge Bioscience LightOx Twist Bioscience www.bioscience.co.uk www.lightox.co.uk www.twistbioscience.com Cambridge Research Biochemicals Medicines Discovery Catapult UPM-Kymmene Corporation www.crbdiscovery.com www.md.catapult.org.uk www.upmbiomedicals.com Cancer Research UK Mimetas B.V. XenoGesis Ltd www.cancerresearchuk.org www.mimetas.com www.xenogesis.com CBRE Integrated National Physical Laboratory Zinsser Analytic GmbH Laboratory Solutions www.npl.co.uk www.zinsser-analytic.com www.cbre.co.uk Cell Signaling Technology PAA Ltd www.cellsignal.com www.paa-automation.com

Drug Discovery 2019 Innovation Zone

Atelerix Ltd Cellbox Solutions Manchester BIOGEL www.atelerix.co.uk www.cellbox-solutions.com www.manchesterbiogel.com BioMedha Limited Cytomos Limited Microlight3D www.biomedha.com www.cytomos.com www.microlight3d.com British Society for Nanomedicine Enzymlogic ScreenIn3D www.britishsocietynanomedicine.org www.enzymlogic.com www.screenin3d.com Cell & Soft Imrali Inventions Stream Bio Ltd www.linksium.fr/projet/mecachips www.imraliinvention.com www.streambio.co.uk Cell Guidance Systems innoVitro GmbH www.cellgs.com www.innovitro.de

Drug Discovery 2019 Media Partners

Alderley Park Accelerator Drug Discovery Today SelectScience www.alderleypark.co.uk/accelerator www.drugdiscoverytoday.com www.selectscience.net BioCity Drug Discovery World Technology Networks www.biocity.co.uk/ www.ddw-online.com www.technologynetworks.com Biostrata Drug Target Review UKSPA www.biostratamarketing.com www.drugtargetreview.com www.scienceparks.co.uk UK Pharmacogenetics & British Pharmacological Society European Biopharmaceutical Review Stratified Medicine Network www.bps.ac.uk www.samedanltd.com/magazine/12 www.uk-pgx-stratmed.co.uk Drug Discovery News GEN Zyme Communications www.ddn-news.com www.genengnews.com www.zymecommunications.com

#ELRIG